Santen Pharmaceutical (OTCMKTS:SNPHY) Reaches New 52-Week High – What’s Next?

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY)’s share price reached a new 52-week high on Thursday . The company traded as high as $13.10 and last traded at $13.10, with a volume of 718 shares traded. The stock had previously closed at $12.31.

Analyst Ratings Changes

Separately, Zacks Research upgraded Santen Pharmaceutical to a “hold” rating in a research note on Monday, April 13th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Santen Pharmaceutical Trading Down 2.6%

The firm has a market capitalization of $4.11 billion and a price-to-earnings ratio of 0.10. The stock’s fifty day moving average price is $11.55 and its two-hundred day moving average price is $11.13.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.